Figure 2.

A 70‐yr‐old mCRPC patient with Gleason 4 + 5 who progressed after 20 months on traditional hormone treatment, and 8 docetaxel cycles of chemotherapy. PSMA imaging both before and after 12 weeks of abiraterone treatment showed a decrease in the miPSMA score of the bone lesions (A, red arrow). However, at week 12, there was a significant increase in the PSA and 2 new lesions on the bone scan (B, red circle). By weeks 20‐28, the PSA progression improved, and no additional lesions appeared on the bone scan, indicating that the progression seen at week 12 was due to PSA and a bone flare